Study of TQB2102 for HER2-negative breast cancer that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-negative breast cancer that has spread to other parts of the body and cannot be cured with surgery or radiation.
- You tried at least one type of chemotherapy for the spread cancer, and it either stopped working or caused side effects you couldn't handle.
- You have a tumor that can be measured on a scan (like a CT or MRI).
- You have not had any other cancer (except for some skin cancers) in the last 5 years.
- You are willing to use birth control during and for 6 months after the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial tests an investigational drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to see how safe the drug is and how the body processes it, and it may offer a new option for those with few alternatives.
This study tests a new drug called TQB3126 for people with breast cancer that has gotten worse after previous treatments. The goal is to see if the drug is safe and helps shrink or slow the cancer.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.